Table 4. Hazard ratios for 9 HT protocols, consisting of women who took HT at least 5 years, relative to a control group consisting of women who did not take any HT, 95% confidence intervals for the hazard ratios, and p-values obtained using the one-sided log-rank test, where the null hypothesis is that the area under the survival curve for the control group is smaller than or equal to the area under the survival curve for the HT group.
| HT Protocol | HR (95% CI) | p-Value | # Cases | # BC Cases (%) |
|---|---|---|---|---|
| CEE Alone | 0.28 (0.16, 0.49) | 4.19×10−6 | 415 | 12 (2.89%) |
| MPA Alone | NA | NA | NA | NA |
| Other Synthetic Estrogen Alone | 1.44 (0.72, 2.9) | 0.15 | 72 | 8 (11.11%) |
| Other Synthetic Progesterone Alone | NA | NA | NA | NA |
| Bioidentical Estrogen Alone | 0.72 (0.37, 1.39) | 0.16 | 156 | 9 (5.77%) |
| Bioidentical Progesterone Alone | 1.05 (0.15, 7.48) | 0.48 | 19 | 1 (5.26%) |
| CEE & MPA | 0.75 (0.31, 1.8) | 0.26 | 78 | 5 (6.41%) |
| Other Synth. Estr. & Synth. Prog. | 0.83 (0.44, 1.5) | 0.27 | 225 | 10 (4.44%) |
| Bioid. Estrogen & Bioid. Prog. | 1.46 (0.54, 3.81) | 0.32 | 51 | 4 (7.84%) |
Only women initiating drug usage after 01/01/2004 are included. The number of controls was 24,301, and the number of controls realizing breast cancer was 2016.